Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

Background: We conducted a meta-analysis to evaluate the efficacy and safety of upfront add-on immunotherapy for advanced non-small cell lung cancers (NSCLC). Methods: We performed a literature search on first-line chemotherapy ± immunotherapy in NSCLC. We utilized Revman version 5.3 to calculate th...

Full description

Bibliographic Details
Published in:	Future Science OA
Main Authors:	Aung Myint Tun, Kyaw Zin Thein, Wai Lin Thein, Elizabeth Guevara
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2019-10-01
Subjects:	advanced non-small-cell lung cancer checkpoint inhibitors chemotherapy first-line therapy immune-related adverse events objective response rate
Online Access:	https://www.future-science.com/doi/10.2144/fsoa-2019-0081

Similar Items

Application of Immune Checkpoint Inhibitors in Cancer
by: Zhijun Chen, et al.
Published: (2025-08-01)

The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis
by: Ting Mei, et al.
Published: (2023-02-01)

First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis
by: Shuo Kang, et al.
Published: (2022-01-01)

Association Between Immune‐Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study
by: Kazumasa Yamamoto, et al.
Published: (2025-09-01)

Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis
by: Yanfeng Jiang, et al.
Published: (2021-09-01)

Immune checkpoint inhibitors and cancer-related cognitive decline: a propensity score matched analysis in active chemotherapy patients
by: Guangmin Jian, et al.
Published: (2025-03-01)

Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis
by: Xuewen Zhang, et al.
Published: (2024-05-01)

Chemotherapy combined with regorafenib and immune checkpoint inhibitors as a first-line treatment for patients with advanced biliary tract cancer: a single arm phase II trial
by: Jianwei Liu, et al.
Published: (2024-09-01)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
by: Yu Lu, et al.
Published: (2023-01-01)

The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma
by: Tang X, et al.
Published: (2024-10-01)

Immune checkpoint inhibitor-induced cardiotoxicity in patients with lung cancer: a systematic review and meta-analysis
by: Naser Yamani, et al.
Published: (2024-06-01)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
by: Tingting Lu, et al.
Published: (2023-07-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01)

Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms
by: Rishi Rikhi, et al.
Published: (2021-08-01)

Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer
by: Guisen Yin, et al.
Published: (2025-01-01)

Pancreatic adverse events in patients treated with immune checkpoint inhibitors
by: Caroline Hana, et al.
Published: (2023-03-01)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
by: Zhou Zhu, et al.
Published: (2023-10-01)

Hepatobiliary complications of immune checkpoint inhibitors in cancer
by: Donna Zhuang, et al.
Published: (2024-07-01)

Neurotoxicity in the Era of Immune Checkpoint Inhibitors: A Case-Based Approach
by: Özkan ALAN, et al.
Published: (2025-04-01)

Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review
by: Elizabeth S Mearns, et al.
Published: (2018-03-01)

Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study
by: Xue Zhang, et al.
Published: (2024-12-01)

Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
by: Cecilia Olsson Ladjevardi, et al.
Published: (2023-06-01)

Immune checkpoint inhibitor-induced inflammatory arthritis
by: Benjamin A. Fisher, et al.
Published: (2025-09-01)

Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis
by: Baohui Hong, et al.
Published: (2024-02-01)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
by: Peng Song, et al.
Published: (2020-08-01)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
by: Linyang Gan, et al.
Published: (2023-03-01)

Hepatotoxicity induced by immune checkpoint inhibitors
by: Flaviu Muresan, et al.
Published: (2024-10-01)

Patterns of hormonal changes in hypophysitis by immune checkpoint inhibitor
by: Hyunji Sang, et al.
Published: (2024-09-01)

Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma
by: Maximilian Haist, et al.
Published: (2022-03-01)

Clinical significance of combination of anti-angiogenesis, immune checkpoint inhibitors and chemotherapy in the neoadjuvant treatment of locally advanced gastric cancer
by: ZHU Zhenggang
Published: (2024-03-01)

Correlation of multiple endpoints in the first‐line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials
by: Hiroyuki Arai, et al.
Published: (2024-01-01)

Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial
by: Xiao Yang, et al.
Published: (2025-08-01)

Research progress of immune checkpoint inhibitor related autoimmune hypophysitis
by: LI Jia-yi, XING Bing
Published: (2020-03-01)

Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors
by: Bruno Fattizzo, et al.
Published: (2022-04-01)

Toxicity in the era of immune checkpoint inhibitor therapy
by: Synat Keam, et al.
Published: (2024-08-01)

Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
by: Shengxiu He, et al.
Published: (2023-10-01)

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
by: Cecilia Olsson Ladjevardi, et al.
Published: (2024-06-01)

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors
by: Parneet K. Cheema, et al.
Published: (2024-10-01)

A case of severe acute hemorrhagic duodenitis after administration of immune checkpoint inhibitor
by: Keita Saito, et al.
Published: (2022-04-01)